Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer

OncoTargets and Therapy
Xiaoguang XiaoYuan Chen

Abstract

Much research has confirmed the favorable effect of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) on extensive-stage small cell lung cancer (E-SCLC). This study investigated two sequential orders of IP and EP in the treatment of E-SCLC. We also compared the efficacy and safety of IP and EP in first-line chemotherapy in E-SCLC. Ninety-three untreated patients with E-SCLC were randomly allocated to two groups. Group A received IP as first-line therapy until progression and then changed to EP; group B received EP as first-line therapy until tumor progression followed by IP. The primary endpoints were overall survival and time to second tumor progression. The secondary endpoints were first progression-free survival (PFS), ie, time from randomization to first occurrence of tumor progression after first-line treatment with IP or EP, tumor response, and safety of the different sequential treatment orders of IP and EP. Median overall survival was 15.4 months in group A (IP followed by EP) versus 15.7 months in group B (EP followed by IP; P=0.483). The median time to second tumor progression was 9.5 months in group A versus 9.9 months in group B (P=0.361). As first-line and second-line therapy, IP achieved a 95.9% and 60% disea...Continue Reading

Citations

Nov 20, 2016·Journal of the Egyptian National Cancer Institute·Pramod K JulkaGoura K Rath
May 28, 2019·Clinical Journal of Gastroenterology·Yuki KanekoNaohiro Sata
Nov 15, 2018·International Journal of Molecular Sciences·Anna Lichota, Krzysztof Gwozdzinski
Jan 20, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Gavin S JonesTricia M McKeever

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

Statistical Package for the Social Sciences

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.